Overview

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

Status:
Recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effects on electrical activity in the brain of an investigational drug (RL-007) for improving cognition in patients with schizophrenia
Phase:
Phase 2
Details
Lead Sponsor:
Recognify Life Sciences